Xeris Biopharma Holdings Inc. Stock
The Xeris Biopharma Holdings Inc. stock is trending slightly upwards today, with an increase of €0.010 (0.190%) compared to yesterday's price.
With 12 Buy predictions and not the single Sell prediction the community is currently very high on Xeris Biopharma Holdings Inc..
As a result the target price of 8 € shows a very positive potential of 56.25% compared to the current price of 5.12 € for Xeris Biopharma Holdings Inc..
Pros and Cons of Xeris Biopharma Holdings Inc. in the next few years
Pros
?
W********* I********* f** t** n*** y****
?
G***** c******* t* c**********
?
B****
Cons
?
S********** s********
?
M***** P*******
?
C******** o* t** e**********
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Xeris Biopharma Holdings Inc. vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Xeris Biopharma Holdings Inc. | 0.190% | -9.700% | -17.486% | 45.207% | -18.923% | 274.214% | 19.626% |
| Heron Therapeutics Inc. | -0.780% | 7.922% | -15.362% | -53.787% | -10.727% | -54.381% | -93.065% |
| Evolus Inc | -2.170% | -1.099% | -9.091% | -73.333% | -33.945% | -57.647% | -68.324% |
| Sangamo Therapeutics Inc. | -5.110% | -17.135% | 1.848% | -61.932% | -3.917% | -87.393% | -96.382% |
Comments
Xeris Biopharma (XERS) had its "buy" rating reaffirmed by HC Wainwright. They now have a $10.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $10.00 price target on the stock.
Show more
Ratings data for XERS provided by MarketBeat
Xeris Biopharma (NASDAQ:XERS) is now covered by analysts at Barclays PLC. They set an "overweight" rating on the stock.
Show more
Ratings data for XERS provided by MarketBeat